Neurizon's ALS Drug Trial Races Ahead, Shortening Wait for Critical Data

MELBOURNE, Australia – July 16, 2026

In a significant development for the amyotrophic lateral sclerosis (ALS) community, Australian biotech firm Neurizon Therapeutics announced today the successful completion of enrollment for a pivotal trial of its lead drug candidate, NUZ-001. The speed of recruitment shattered previous records for the prestigious HEALEY ALS Platform Trial, allowing the company to accelerate the timeline for its much-anticipated topline results to the second quarter of 2027.

The trial, designated Regimen I, enrolled 250 participants in under five months, a feat made more impressive by a planned expansion from 160 participants due to overwhelming interest. This rapid progress is a critical operational victory for Neurizon and a powerful signal of the urgent, unmet need within the ALS patient population. Participants will now move through a 36-week randomized, placebo-controlled treatment period.

"Completion of enrolment represents a major milestone in the clinical development of NUZ-001," said Neurizon's Interim Executive Chairman, Mr. Sergio Duchini. "Importantly, the rapid completion of recruitment has enabled the anticipated timing of topline efficacy and safety results to be accelerated into late Q2 2027, bringing forward an important value inflection point for Neurizon and our shareholders."

A Race Against the 'ALS Clock'

Today's announcement offers a tangible surge of hope in the relentless fight against ALS, a brutal and progressive neurodegenerative disease that attacks nerve cells in the brain and spinal cord. For the estimated 30,000 Americans and hundreds of thousands more worldwide living with the condition, the prognosis is grim, with a median survival of just two to five years post-diagnosis. The disease relentlessly strips away muscle control, leading to paralysis and eventual respiratory failure.

The current treatment landscape offers only modest benefits. Drugs like Riluzole may extend survival by a few months, while others can slow functional decline to a limited degree. The high-profile withdrawal of Amylyx Pharmaceuticals' Relyvrio earlier this year, after it failed a confirmatory Phase 3 trial, served as a stark reminder of the immense difficulty in developing effective therapies. This challenging backdrop makes the efficiency of the HEALEY trial and the speed of Neurizon's progress all the more significant.

"Our patients tell us that the ALS clock is faster and we need to work collaboratively to develop treatments sooner," said Dr. Merit Cudkowicz, Director of the Sean M. Healey & AMG Center at Mass General Brigham, which leads the trial. This sentiment is the driving force behind the platform trial's innovative design and is echoed by the patient community.

"An accelerated timeline isn't just a data point on a chart; for families living with this disease, it represents a tangible acceleration of hope," commented a representative from a leading patient advocacy group. "The willingness of 250 individuals and their families to commit to this research, and the ability of the trial network to accommodate them so quickly, is inspiring. It shows a unified front against a common enemy."

The HEALEY Platform: A New Blueprint for Biotech

The unprecedented speed of the NUZ-001 trial is not just a story about one drug, but also about the groundbreaking research model that made it possible. The HEALEY ALS Platform Trial is revolutionizing how therapies for complex diseases are tested, moving away from the slow, siloed, and costly traditional clinical trial process.

Conceived by the Sean M. Healey & AMG Center and conducted in partnership with the Network of Excellence for ALS (NEALS), the platform trial is an adaptive, multi-center study designed to test multiple drug candidates simultaneously. Instead of each drug requiring its own separate trial with a dedicated placebo group, multiple regimens share a common placebo arm. This structure is profoundly more efficient. It reduces the total number of participants required, shortens trial timelines, and, critically, increases the probability that a participant will receive an active investigational drug rather than a placebo—a crucial ethical consideration in a fatal disease.

"The platform model is a paradigm shift," noted an independent clinical trial expert. "Instead of building a new ship for every voyage, we have an aircraft carrier that can launch multiple sorties at once. It's the only way to make meaningful progress against complex, heterogeneous diseases like ALS."

The model's adaptive design allows researchers to add new drug regimens as they become available and drop those that prove ineffective, ensuring that resources are perpetually focused on the most promising science. The rapid enrollment of NUZ-001's regimen, which Dr. Cudkowicz called "a testament to the hard work of participants and their families and study staff," validates the platform's core principle: to accelerate the path from lab bench to bedside.

Neurizon's High-Stakes 'Value Inflection Point'

For Neurizon Therapeutics, a late-stage clinical company listed on the ASX and OTCQB, completing enrollment is a crucial de-risking event. The operational hurdles of site activation and patient recruitment—often major stumbling blocks for biotech firms—are now in the rearview mirror. The company's fate, and that of its lead asset, now hinges almost entirely on the clinical data.

As Mr. Duchini stated, this milestone brings forward a "value inflection point." In biotech investing, this refers to a pivotal event that can dramatically re-shape a company's valuation. A positive result for NUZ-001 in 2027 could unlock immense value in a market desperate for better treatments. Conversely, a failure would be a major setback. While the company has not publicly detailed the specific scientific mechanism of NUZ-001, its selection for the competitive HEALEY trial implies a strong scientific rationale.

The competitive landscape for ALS is fierce, but the bar for a clinically meaningful improvement remains achievable. Biogen's Qalsody, approved in 2023, offered a breakthrough for a small subset of patients with a specific SOD1 gene mutation, proving that targeting the disease's underlying genetics can work. A drug that could offer significant benefits to the broader, sporadic ALS population would be a blockbuster. By successfully navigating the HEALEY platform's efficient pathway, Neurizon has positioned itself for a high-stakes, high-reward outcome.

The Path to 2027 and Beyond

With recruitment now complete, the focus for Neurizon and the HEALEY trial team shifts to meticulous execution over the next year. The 250 participants will proceed through the 36-week randomized controlled phase, after which they can enter a 36-week active treatment extension, ensuring long-term data collection. Maintaining the integrity of the study during this period is paramount to delivering a clear and unambiguous result.

Mr. Duchini affirmed this focus: "Our focus turns to delivering the study with the same operational discipline that has characterised the program to date." He extended his sincere thanks to the trial participants, their families, and the vast network of clinical site teams whose commitment made the rapid enrollment possible.

The progress of NUZ-001 unfolds within a dynamic global research environment. The European Medicines Agency is currently updating its clinical trial guidance for ALS, and scientists continue to identify novel therapeutic targets, signaling a field ripe with innovation. With enrollment complete, the focus of patients, researchers, and investors now converges on a single point in the not-so-distant future: the late second quarter of 2027, when the data will finally speak.